vesemnogene lantuparvovec
Gene therapyexperimental
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
1
Phase 4
0
Earliest trial started Oct 20, 2024 (NCT06288230)
Timeline
Indications
Studied for
Mechanism of action
- Survival motor neuron proteinSupplementation
SMN1 supplementation
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07265232 | Phase 3 | Oct 15, 2025 | Government of China |
| NCT06288230 | Phase 1/Phase 2 (Phase 2) | Oct 20, 2024 | Government of China |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Government of China | Government | 2 | 2 | 2 | 2024 |
1 organizations
Page 1 / 1